Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Actinium Pharmaceuticals, Inc. successfully completes the first closing of $5.1 million in its ongoing funding raise
Actinium Pharmaceuticals, Inc., a leader in the field of alpha radioimmunotherapy for cancer closed on the first tranche in its common stock offering with Laidlaw & Company (UK) Ltd. as exclusive placement agent

NEW YORK, Dec. 26, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc., a leader in the field of alpha radioimmunotherapy for treatment of advanced cancers, is pleased to announce that it has successfully completed a first closing of $5.1 million in its current round of financing, for which Laidlaw & Company (UK) Ltd. is exclusive placement agent. Funding will be used primarily for further development of Actimab‐A, Actinium's lead drug candidate in multicenter Phase I/II trials in Acute Myeloid Leukemia (AML) and Iomab – B, a Phase II clinical stage bone marrow conditioning agent for preparing patients for hematopoietic stem cell transplantation. 

Jack Talley, President and CEO of Actinium, said: "This raise allows us to aggressively continue our clinical programs aimed at helping acute myeloid leukemia patients who have few or no other options today and very little time to wait.  We are addressing almost completely unmet medical needs with both of our drug candidates."

Under the terms of the offering the Company sold approximately 9.3 million shares of common stock and issued 9.3 million warrants at $0.55 per share which expire 120 days from the final closing of the offering and approximately 4.6 million warrants at an exercise price of $0.825 per share which expire five years after the final close of the offering.  The Company is authorized to sell up to $15 million in gross proceeds and is allowed to keep the offering open until January 31, 2013. The Company is planning to go public via a reverse merger prior to year end.  As part of that process the Company is currently soliciting consents to exchange private shares for public shares in a one for three reverse split. Post the reverse merger transaction, the offering will continue on the same terms on a pro-forma basis with the common shares offered at $1.65 per share, the 120 day warrants exercise price at $1.65 per share and the 5 year warrants exercise price at $2.48 per share.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc.  is a New York, New York based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 isotopes in association with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

About Laidlaw & Company, LTD.  

Laidlaw & Company is a full service investment bank and securities brokerage firm with offices in New York, London, San Francisco and select additional locations. Its corporate finance efforts are focused on the healthcare, natural resource and social commerce sectors. In addition to capital raising, its investment banking arm provides M&A, restructuring and other financial advisory services for public and private small cap and middle market clients across a broad cross section of industry sectors. Its brokerage arm provides wealth management services for domestic and international high net worth and institutional clients.  Laidlaw is a member of FINRA and SIPC. 

For more information:

Visit our web site www.actiniumpharmaceuticals.com or contact:

Media:
Dennis S. Dobson Jr.
Tel: 203-258-0159
Email: dsdobson@optonline.com
www.dobsonmediagroup.com

Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel:  (646) 459-4201
E-mail: actimaba@actiniumpharmaceuticals.com


Investors:
Jeff Ramson
ProActive Capital Group, LLC
Tel:  (646) 863-6341
E-mail: jramson@proactivecrg.com    
www.proactivecrg.com  

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
Storage administrators find themselves walking a line between meeting employees’ demands to use public cloud storage services, and their organizations’ need to store information on-premises for security, performance, cost and compliance reasons. However, as file sharing protocols...
With the rapid advancement of processor technologies, disk access has been identified as the next performance bottleneck in many cloud computing applications. In recent years, storage appliances based on flash memory technologies have been deemed as practical solutions to resolvi...
What do a firewall and a fortress have in common? They are no longer strong enough to protect the valuables housed inside. Like the walls of an old fortress, the cracks in the firewall are allowing the bad guys to slip in – unannounced and unnoticed. By the time these thieves get...
In this challenging environment, a combination of automated integration testing and test virtualization can enable test teams to improve software quality and keep up with the rate of change. This white paper helps address these needs by describing the benefits that can be gained ...
Fundamentally, SDN is still mostly about network plumbing. While plumbing may be useful to tinker with, what you can do with your plumbing is far more intriguing. A rigid interpretation of SDN confines it to Layers 2 and 3, and that’s reasonable. But SDN opens opportunities for n...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE

Breaking Cloud Computing News
delivering unmatched performance, major new graphics capabilities and twice the energy efficiency of...